27 May 2021 14:11
Vectura Group plc
Appointment of Senior Independent Director
Chippenham, UK - 27 May 2021: Vectura Group plc (LSE: V EC) ("Vectura" or "the Group") announces that, as reported in our 2020 Annual Report and Accounts, following the Annual General Meeting Dr Thomas Werner stepped down as a Non-Executive Director and the Senior Independent Director, roles he has held since 2009 and 2019 respectively.
With effect from the close of the Annual General Meeting, Jeanne Thoma has been appointed as the Senior Independent Director of the Company.
Bruno Angelici, Chairman of the Board, said: "Thomas' contribution, initially to Skyepharma and later to Vectura, has been remarkable. His deep experience and business judgement will be missed. We are delighted that Jeanne Thoma will be taking up the role as the new Senior Independent Director."
- Ends-
For more information, please contact:
Vectura Group plc
John Murphy - Company Secretary +44 (0)207 881 1206
Olivia Manser - Director, Investor Relations +44 (0)7947 758 259
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Melissa Gardiner / David Daley
About Vectura
Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has twelve key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com